Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib 800 mg/day in Asian patients with metastatic or unresectable GIST harboring KIT exon 9 mutation
KCT0008415Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Started Nov 2012; status: recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on KCT0008415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008415.